Studies related to C-Reactive Protein (CRP) and Resveratrol

Cardioprotection By Resveratrol: A Human Clinical Trial In Patients With Stable Coronary Artery Disease

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 40
Sex Both Genders
Age Range 45-64, 65+
Body Types Overweight
Notes for this study:
In patients after myocardial infarction, trans-resveratrol at 10mg daily for 3 months increased Flow Mediated Vasodilation (biomarker for blood flow) and increased left ventricular heart function. Unsure whether improvement in ventricular function is applicable to all persons of only those after myocardial infarction.

Also decreased LDL cholesterol (2.7 relative to control's 3.15mmol/L). HbA1c levels (marker of diabetes risk) showed a beneficial trend, but did not reach statistical significance.